Author(s)

El Hadji Amadou Lamine Bathily^1,2*, Mamoudou Salif Djigo², Djimby Ba¹, Gora Thiaw^1,2, Ousseynou Diop^2,3, Kalidou Gueye¹, Olatounde Herbert Fachinan⁴, Boucar Ndong^2,3, Omar Ndoye², Mamadou Mbodj^1,2

¹Nuclear Medicine Department, Idrissa Pouye General Hospital (HOGIP), Dakar, Senegal.
²Biophysics Laboratory, FMPO, UCAD, Dakar, Senegal.
³Nuclear Medicine Department, Hospital Dalal Jamm, Dakar, Senegal.
⁴Nursing and Obstetrics Training Institute, Parakou University, Parakou, Benin.

Introduction: Breast cancer is the most common cancer in women worldwide, accounting for an estimated 22% of all female cancers. It is the leading cause of cancer mortality in women, almost all of which is due to metastases, with 73% of metastases occurring in the bone. In oncology, metastable technetium 99-labelled methylene bisphosphonate bone scintigraphy (BS) remains the standard examination for detecting and assessing the extent of bone metastases. The aim of this study was to assess the role of BS in the evaluation and follow-up of breast cancer in Senegal. Methodology: This was a retrospective study of breast cancer patients who underwent bone scintigraphy with ^99mTc-HMDP in the nuclear medicine department of Idrissa Pouye General Hospital (IPGHO), from July 2009 to June 2022. Results: We enrolled 165 patients, mean age 46.79 years (27 - 87 years). BS was performed in 94.37% of cases for post-therapeutic monitoring and in 5.63% for pre-therapeutic assessment. Results were contributory in 131 patients (92.25%), of whom 72 cases (50.70%) were normal and 59 cases (41.55%) positive or presenting bone metastases; and non-contributory or doubtful in 11 cases (7.75%). Secondary bone locations were multiple in 57 cases (96.61%) and single or solitary in 2 cases (3.39%). The scintigraphic appearance of bone metastases was hyper-fixative in 58 cases (98.31%) and mixed in 1 case (1.69%). Bone lesions were quantified using the Soloway’s grading classification. Conclusion: BS with ^99mTc-labelled bisphosphonates remains the examination of choice for skeletal exploration, in the detection and extension of bone metastases in breast cancer. Performance has been enhanced by the development of SPECT coupled with CT (SPECT-CT).

Breast Cancer, Bone Scintigraphy, ^99mTc-HMDP, Bone Metastases

Bathily, E. , Djigo, M. , Ba, D. , Thiaw, G. , Diop, O. , Gueye, K. , Fachinan, O. , Ndong, B. , Ndoye, O. and Mbodj, M. (2024) Place of Bone Scintigraphy in the Assessment of Extension and Follow-Up of Breast Cancer in Senegal: Study of 165 Cases in the Nuclear Medicine Department of Idrissa Pouye General Hospital (Dakar). Open Journal of Medical Imaging, 14, 10-30. doi: 10.4236/ojmi.2024.141002.